A Trump administration proposal to require drug makers to advertise prices in television ads could dissuade consumers from considering pricey medicines, according to a new study. But this reaction was mitigated when ads mentioned some patients may be able to receive the treatment for nothing, which is language that drug makers are pushing to include in the White House scheme.

The researchers showed five different ads to 580 people about a fictitious diabetes drug. One ad did not mention price, another indicated the drug cost $50 a month, and still another cited $15,500 a month. Two other ads also mentioned each price, respectively, but added a line that “eligible patients” may be able to get the drug for as little as $0 a month, according to the study in JAMA Internal Medicine.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Not that there is any “law” (regulation) to actually denigrate yet, to quote from Charles Dickens “The law is an ass!” [God bless you, Mr & Mrs Bumble …]

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy